Advertisement
INFU vs VREX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INFU is a Buy and VREX is a Hold.
Aroon Indicator for INFU shows an upward move is likely
INFU's Aroon Indicator triggered a bullish signal on November 02, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 143 similar instances where the Aroon Indicator showed a similar pattern. In 104 of the 143 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on INFU as a result. In 79 of 116 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for INFU just turned positive on November 10, 2026. Looking at past instances where INFU's MACD turned positive, the stock continued to rise in 43 of 64 cases over the following month. The odds of a continued upward trend are 67%.
INFU moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +11.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where INFU advanced for three days, in 175 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Bearish Trend Analysis
The 10-day RSI Indicator for INFU moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 16 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INFU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
INFU broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. INFU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 56 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.610) is normal, around the industry mean (4.142). P/E Ratio (32.595) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.180) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.817) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INFU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
VREX in +0.54% Uptrend, rising for three consecutive days on November 03, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where VREX advanced for three days, in 195 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VREX as a result. In 62 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
VREX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VREX crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VREX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
VREX broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VREX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. VREX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.577) is normal, around the industry mean (4.142). P/E Ratio (34.148) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (4.979) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.903) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VREX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
INFU | VREX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 88 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 86 | 100 | |
SMR RATING 1..100 | 56 | 84 | |
PRICE GROWTH RATING 1..100 | 37 | 38 | |
P/E GROWTH RATING 1..100 | 71 | 7 | |
SEASONALITY SCORE 1..100 | 42 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INFU's Valuation (74) in the Medical Specialties industry is in the same range as VREX (90). This means that INFU’s stock grew similarly to VREX’s over the last 12 months.
INFU's Profit vs Risk Rating (86) in the Medical Specialties industry is in the same range as VREX (100). This means that INFU’s stock grew similarly to VREX’s over the last 12 months.
INFU's SMR Rating (56) in the Medical Specialties industry is in the same range as VREX (84). This means that INFU’s stock grew similarly to VREX’s over the last 12 months.
INFU's Price Growth Rating (37) in the Medical Specialties industry is in the same range as VREX (38). This means that INFU’s stock grew similarly to VREX’s over the last 12 months.
VREX's P/E Growth Rating (7) in the Medical Specialties industry is somewhat better than the same rating for INFU (71). This means that VREX’s stock grew somewhat faster than INFU’s over the last 12 months.
| INFU | VREX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | N/A |
| Stochastic ODDS (%) | 2 days ago 84% | 2 days ago 55% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 65% |
| MACD ODDS (%) | 2 days ago 67% | N/A |
| TrendWeek ODDS (%) | 2 days ago 69% | 2 days ago 73% |
| TrendMonth ODDS (%) | 2 days ago 75% | 2 days ago 72% |
| Advances ODDS (%) | 2 days ago 66% | 9 days ago 63% |
| Declines ODDS (%) | 9 days ago 79% | 7 days ago 74% |
| BollingerBands ODDS (%) | 2 days ago 83% | 2 days ago 67% |
| Aroon ODDS (%) | 2 days ago 73% | 2 days ago 74% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INFU’s FA Score shows that 0 FA rating(s) are green while VREX’s FA Score has 1 green FA rating(s).
- INFU’s FA Score: 0 green, 5 red.
- VREX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INFU’s TA Score shows that 5 TA indicator(s) are bullish while VREX’s TA Score has 2 bullish TA indicator(s).
- INFU’s TA Score: 5 bullish, 4 bearish.
- VREX’s TA Score: 2 bullish, 6 bearish.
Price Growth
INFU (@Medical/Nursing Services) experienced а +19.37% price change this week, while VREX (@Medical/Nursing Services) price change was -0.43% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
Reported Earning Dates
INFU is expected to report earnings on Mar 17, 2027.
VREX is expected to report earnings on Nov 17, 2026.
Industries' Descriptions
@Medical/Nursing Services (-2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
INFU and
Correlation & Price change
A.I.dvisor indicates that over the last year, INFU has been loosely correlated with AMIX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if INFU jumps, then AMIX could also see price increases.
| Ticker / NAME | Correlation To INFU | 1D Price Change % | ||
|---|---|---|---|---|
| INFU | 100% | +4.09% | ||
| AMIX - INFU | 43% Loosely correlated | +8.82% | ||
| VREX - INFU | 42% Loosely correlated | N/A | ||
| ICUI - INFU | 39% Loosely correlated | +1.82% | ||
| BFLY - INFU | 36% Loosely correlated | -2.40% | ||
| ANIK - INFU | 33% Loosely correlated | -7.55% | ||
More | ||||
VREX and
Correlation & Price change
A.I.dvisor indicates that over the last year, VREX has been loosely correlated with NVST. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if VREX jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To VREX | 1D Price Change % | ||
|---|---|---|---|---|
| VREX | 100% | N/A | ||
| NVST - VREX | 51% Loosely correlated | -0.50% | ||
| ATR - VREX | 47% Loosely correlated | -0.01% | ||
| A - VREX | 47% Loosely correlated | -1.27% | ||
| ISRG - VREX | 43% Loosely correlated | -2.28% | ||
| DHR - VREX | 43% Loosely correlated | +0.42% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| LAPR | 25.10 | 0.06 | +0.24% |
| Innovator Premium Income 15 Buffer ETF - April (LAPR) | |||
| SDVY | 42.93 | 0.05 | +0.12% |
| First Trust SMID Cap Rising Dividend Achievers ETF (SDVY) | |||
| QLVD | 35.31 | N/A | N/A |
| Northern Trust Developed Markets ex-US Quality Low Volatility ETF (QLVD) | |||
| QSPT | 34.63 | -0.12 | -0.35% |
| FT Vest Nasdaq-100 Buffer ETF - September (QSPT) | |||
| FPXI | 60.65 | -0.59 | -0.97% |
| First Trust International Equity Opportunities ETF (FPXI) | |||